Chondral Injury of the Knee: Current Controversies in 2019 (AANA19)-Evaluation of _New_ Cartilage Repair Options-Dr. Jack Farr, M.D.

Evaluation of _New_ Cartilage Repair Options-Dr. Jack Farr, M.D.

Video Transcription

Video Summary

The speaker discusses challenges in cartilage restoration, emphasizing FDA regulations (HCTP 351 vs. 361) and expensive, lengthy randomized controlled trials (RCTs) that limit new treatments. Many products are FDA-allowed (361) but not approved due to minimal manipulation criteria, impacting insurance coverage. He highlights experiences with sterilized acellular allografts, particulated autografts, and cryopreserved cartilage, noting variable success and high failure rates in some cases. The speaker advises cautious clinical adoption: thorough literature review, small initial case numbers, and outcome monitoring. Ultimately, only MACI is FDA-approved; other therapies require careful evaluation and ongoing follow-up for safety and efficacy.

Asset Caption

Instructional Course Lecture: Chondral Injury of the Knee: Current Controversies in 2019

Keywords

cartilage restoration

FDA regulations

randomized controlled trials

acellular allografts

MACI approval